Peer-reviewed
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
Philip W Kantoff, T Ahmed, Celestia S Higano, Neal D Shore, E Roy Berger, Eric J Small, David F Penson, Charles H Redfern, Anna C Ferrari, Robert Dreicer, Robert B Sims, Yi Xu, Mark W Frohlich, Paul F Schellhammer, A Amin, J Arseneau, N Barth, G Bernstein, B Bracken, P Burch, V Caggiano, J Chin, G Chodak, F Chu, J Corman, B Curti, N Dawson, J F Deeken, T Dubernet, M Fishman, R Flanigan, F Gailani, L Garbo, T Gardner, E Gelmann, D George, T Godfrey, L Gomella, M Guerra, S Hall, J Hanson, R Israeli, E Jancis, M A S Jewett, V Kassabian, J Katz, L Klotz, K Koeneman, H Koh, R Kratzke
Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer
Article, 2010